A groundbreaking study documented superior therapeutic properties of the CBD-rich phytocomplex of an extract compared to the single CBD molecule.

 

Israel is still the protagonist of an important step forward in cannabis research.

Published in the pharmacology monthly "Pharmacology & Pharmacy", the article directly challenges one of the axioms of Big Pharma and the other "Big" of the drug, according to which preparations with phytocomplex possess a greater degree of efficiency than the pure single molecule.

 

Lumir Hanus and two of his colleagues from the University of Jerusalem, examining the scientific literature, noted that during the past fifteen years, numerous preclinical studies have focused on the anti-inflammatory effects on animals of the single CBD molecule.

These studies showed that administration of the single, pure CBD molecule results in a dose-response bell curve. This means that when the dose of CBD is exceeded at some point, its therapeutic impact tends to drop dramatically.

 

"The healing process was only noticed when CBD was administered within a very limited range, while no beneficial effect was achieved with a higher or lower dosage," the authors note.

The characteristic of the single CBD molecule has put research on the same at risk for several years.

The Israeli team set itself the goal, that of demonstrating that a CBD extract containing the phyto-complex has greater therapeutic qualities: "The purpose of this study, explain the authors, was to find a source of CBD that would solve the problem. of the bell dose response, which pure CBD has been shown to have.

Scientists have obtained a high-percentage CBD strain called “Avidekel” from Tikkun Olam, an Israeli cannabis producer. In the study, the strain bears the name of "clone 202". We can trace the genetics of this strain as far as Spain, where breeders have developed different phenotypes of Cannatonic, including a strain that has reached a percentage of 20% of CBD in the dried inflorescence.

Israeli researchers extracted a CBD-rich oil from the “Clone 202” strain. The extract contained 17.9% CBD; 1.1% THC and 1.1% CBC; 0.2% CBG and traces of CBN and CBDV demonstrating very valid anti-inflammatory and anti-pain effects.

 

For comparative purposes, the researchers administered pure CBD to another group of mice and evaluated its analgesic properties, comparing it with a preparation containing the phytocomplex.

 

The results speak for themselves: Israeli studies show that an extract of the "Clone 202" strain "is significantly superior to the single CBD molecule for the treatment of inflammatory conditions."

The greater efficiency of the phytocomplex is answered in the interaction between the different cannabinoids and non-cannabinoid compounds.

"It is as if the other phyto cannabinoids, in synergy with CBD, increase its effectiveness to achieve the anti-inflammatory action".

 

Scientists found it necessary and useful to complete the research project, a comparison analysis between the extracts of the cannabis phytocomplex with a high CBD content with oils and other CBD products on the market. They found that both are more effective than aspirin.

Therefore, in the presence of other cannabinoids, CBD increases the positive response to administration, and this is confirmed by a recent report that documents the anti-proliferating effects of cannabinoids on tumor cells and inhibitors on the contractility of the bladder.

"A lot of research has been carried out with the aim of isolating the individual constituents of traditional medicinal herbs for therapeutic purposes", concludes the Israeli team. “However, our data together with the others legitimize us to introduce a new generation of pesticides for the treatment of diseases and ailments until now treated using only synthetic drugs.

The therapeutic synergy observed in the plant extracts results in a lower presence of the active elements which results in a much sought-after reduction of side effects.

 

Source: www.projectcbd.org